All In Biotech

Drug Trial Radar · NCT06033950

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,600

Planned (sponsor's estimate)

Start

Aug 20, 2024

Primary completion

Aug 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Colorado Prevention CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
St. Luke's Hospital, Kansas City, Missouri; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

Conditions

  • Heart Failure

Interventions

  • FinerenoneDrug

    Oral finerenone.

  • PlaceboDrug

    Matching oral placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of cardiovascular (CV) death or HF event.Time frame: Ongoing, up to ~30 months
  2. Number of serious adverse eventsTime frame: Ongoing, up to ~30 months
  3. Number of adverse events leading to discontinuation of study drug.Time frame: Ongoing, up to ~30 months

Locations

176 sites in 14 countries. Site status is shown where the registry gives one.

  • FIN-10004 Fairhope, AL Investigational Site

    Fairhope, Alabama · Recruiting

  • Phoenix, AZ Investigative Site FIN-10115

    Phoenix, Arizona · Recruiting

  • FIN-10401, Yuma, AZ

    Yuma, Arizona · Recruiting

  • Chula Vista, CA Investigative Site FIN-10419

    Chula Vista, California · Recruiting

  • Chula Vista, CA Investigative Site FIN-10111

    Chula Vista, California · Recruiting

  • FIN-10407, Northridge, CA

    Northridge, California · Recruiting

  • FIN-10412, Orange, CA

    Orange, California · Recruiting

  • FIN-10070, Pamona, CA

    Pomona, California · Recruiting

  • FIN-10024, Sacramento, CA

    Sacramento, California · Recruiting

  • FIN-10406, San Diego, CA

    San Diego, California · Recruiting

  • San Diego, CA Investigative Site FIN-10420

    San Diego, California · Recruiting

  • FIN-10075 San Diego, CA Investigational Site

    San Diego, California · Recruiting

  • San Francisco, CA Investigative Site FIN-10023

    San Francisco, California · Recruiting

  • FIN-10423, Sherman Oaks, CA

    Sherman Oaks, California · Recruiting

  • FON-10409, Tarzana, CA

    Tarzana, California · Recruiting

  • FIN-10109, Van Nuys, CA

    Van Nuys, California · Recruiting

  • FIN-10408, West Covina, CA

    West Covina, California · Recruiting

  • FIN-10013, West Hills, CA

    West Hills, California · Recruiting

  • FIN-10110, Aurora, CO

    Aurora, Colorado · Recruiting

  • FIN-10001, Aurora, CO

    Aurora, Colorado · Recruiting

  • Bradenton, FL Investigative Site FIN-10125

    Bradenton, Florida · Recruiting

  • FIN-10104, Hialeah, FL

    Hialeah, Florida · Recruiting

  • FIN-10028, Jacksonville, FL

    Jacksonville, Florida · Recruiting

  • FIN-10105, Miami, FL

    Miami, Florida · Recruiting

  • FIN-10113, Miramar, FL

    Miramar, Florida · Recruiting

  • FIN-10019, Peoria, IL

    Peoria, Illinois · Recruiting

  • FIN-10064, Merrillville, IN

    Merrillville, Indiana · Recruiting

  • Cynthiana, KY Investigative Site FIN-10124

    Cynthiana, Kentucky · Recruiting

  • FIN-10080, Lexington, KY

    Lexington, Kentucky · Recruiting

  • Lexington, KY Investigative Site FIN-10118

    Lexington, Kentucky · Recruiting

  • FIN-10086, Louisville, KY

    Louisville, Kentucky · Recruiting

  • Louisville, KY Investigative Site FIN-10417

    Louisville, Kentucky · Recruiting

  • FIN-10079, Paducah, KY

    Paducah, Kentucky · Recruiting

  • FIN-10030, Baton Rouge, LA

    Baton Rouge, Louisiana · Recruiting

  • FIN-10106, Hammond, LA

    Hammond, Louisiana · Recruiting

  • FIN-10090, West Monroe, LA

    West Monroe, Louisiana · Recruiting

  • Minneapolis, MN Investigative Site FIN-10035

    Minneapolis, Minnesota · Recruiting

  • FIN-10002 Kansas City, MO Investigational Site

    Kansas City, Missouri · Recruiting

  • FIN-10318, Charlotte, NC

    Charlotte, North Carolina · Recruiting

  • Greenville, NC Investigative Site FIN-10122

    Greenville, North Carolina · Recruiting

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.